Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma

References

• William D. Travis, Elisabeth Brambilla, H. Konrad Müller-Hermelink, Curtis C. Harris, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARCPress International Agency for Research on Cancer (IARC) 2004.
   Google Scholar
• LaDou J, Castleman B, Frank A, Gochfeld M, Greenberg M, Huff J, Joshi TK, Landrigan PJ, Lemen R, Myers J, et al. The case for a global ban on asbestos. Environ Health Perspect 2010; 118:897 - 901; http://dx.doi.org/10.1289/ehp.1002285; PMID: 20601329
   PubMed Web of Science ®Google Scholar
• Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health 2013; 34:205 - 16; http://dx.doi.org/10.1146/annurev-publhealth-031811-124704; PMID: 23297667
   PubMed Web of Science ®Google Scholar
• Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27:2081 - 90; http://dx.doi.org/10.1200/JCO.2008.19.8523; PMID: 19255316
   PubMed Web of Science ®Google Scholar
• Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1:68 - 76; http://dx.doi.org/10.1038/35094077; PMID: 11900253
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307 - 10; http://dx.doi.org/10.1038/35042675; PMID: 11099028
   PubMed Web of Science ®Google Scholar
• Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Gerwin BI, et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 1992; 52:2610 - 5; PMID: 1568228
   PubMed Web of Science ®Google Scholar
• Mor O, Yaron P, Huszar M, Yellin A, Jakobovitz O, Brok-Simoni F, Rechavi G, Reichert N. Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol 1997; 16:9 - 13; http://dx.doi.org/10.1165/ajrcmb.16.1.8998073; PMID: 8998073
   PubMed Web of Science ®Google Scholar
• Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54:5547 - 51; PMID: 7923195
   PubMed Web of Science ®Google Scholar
• Prins JB, Williamson KA, Kamp MM, Van Hezik EJ, Van der Kwast TH, Hagemeijer A, Versnel MA. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998; 75:649 - 53; http://dx.doi.org/10.1002/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2; PMID: 9466670
   PubMed Web of Science ®Google Scholar
• Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, Mellottee L, Fleury-Feith J, Zucman-Rossi J, Giovannini M, Jaurand MC. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle 2005; 4:1862 - 9; http://dx.doi.org/10.4161/cc.4.12.2300; PMID: 16319530
   PubMed Web of Science ®Google Scholar
• Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001; 61:5959 - 63; PMID: 11507034
   PubMed Web of Science ®Google Scholar
• Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F, Jablons DM. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000; 92:636 - 41; http://dx.doi.org/10.1093/jnci/92.8.636; PMID: 10772681
   PubMed Web of Science ®Google Scholar
• Hopkins-Donaldson S, Belyanskaya LL, Simões-Wüst AP, Sigrist B, Kurtz S, Zangemeister-Wittke U, Stahel R. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia 2006; 8:551 - 9; http://dx.doi.org/10.1593/neo.06148; PMID: 16867217
   PubMed Web of Science ®Google Scholar
• Di Cintio A, Di Gennaro E, Budillon A. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis. Recent Pat Anticancer Drug Discov 2010; 5:1 - 13; http://dx.doi.org/10.2174/157489210789702172; PMID: 19663772
   PubMed Web of Science ®Google Scholar
• Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10:1321 - 8; http://dx.doi.org/10.1038/nm1146; PMID: 15558054
   PubMed Web of Science ®Google Scholar
• Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 2010; 9:1847 - 55; http://dx.doi.org/10.4161/cc.9.9.11545; PMID: 20436301
   PubMed Web of Science ®Google Scholar
• Girardini JE, Del Sal G. Improving pharmacological rescue of p53 function: RITA targets mutant p53. Cell Cycle 2010; 9:2062; http://dx.doi.org/10.4161/cc.9.11.11859; PMID: 20559030
   PubMed Web of Science ®Google Scholar
• Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15:171 - 83; http://dx.doi.org/10.1016/j.ccr.2009.01.019; PMID: 19249676
   PubMed Web of Science ®Google Scholar
• Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett 2012; 325:35 - 41; http://dx.doi.org/10.1016/j.canlet.2012.05.020; PMID: 22634494
   PubMed Web of Science ®Google Scholar
• Henze J, Mühlenberg T, Simon S, Grabellus F, Rubin B, Taeger G, Schuler M, Treckmann J, Debiec-Rychter M, Taguchi T, et al. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One 2012; 7:e37776; http://dx.doi.org/10.1371/journal.pone.0037776; PMID: 22662219
   PubMed Web of Science ®Google Scholar
• Musti M, Kettunen E, Dragonieri S, Lindholm P, Cavone D, Serio G, Knuutila S. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 2006; 170:9 - 15; http://dx.doi.org/10.1016/j.cancergencyto.2006.04.011; PMID: 16965949
   PubMed Web of Science ®Google Scholar
• Romagnoli S, Fasoli E, Vaira V, Falleni M, Pellegrini C, Catania A, Roncalli M, Marchetti A, Santambrogio L, Coggi G, et al. Identification of potential therapeutic targets in malignant mesothelioma using cell cycle gene expression analysis. Am J Pathol 2009; 174:762 - 70; http://dx.doi.org/10.2353/ajpath.2009.080721; PMID: 19218339
   PubMed Web of Science ®Google Scholar
• Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, Tsai WY, Santella RM. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 1997; 57:3471 - 7; PMID: 9270015
   PubMed Web of Science ®Google Scholar
• Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9:95 - 107; http://dx.doi.org/10.1038/nrc2584; PMID: 19165225
   PubMed Web of Science ®Google Scholar
• Moran DM, Maki CG. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther 2010; 9:895 - 905; http://dx.doi.org/10.1158/1535-7163.MCT-09-1220; PMID: 20371712
   PubMed Web of Science ®Google Scholar
• Ahmed A, Yang J, Maya-Mendoza A, Jackson DA, Ashcroft M. Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1. Cell Death Dis 2011; 2:e160; http://dx.doi.org/10.1038/cddis.2011.42; PMID: 21593792
   PubMed Web of Science ®Google Scholar
• Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9:400 - 14; http://dx.doi.org/10.1038/nrc2657; PMID: 19440234
   PubMed Web of Science ®Google Scholar
• Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G, Soddu S. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 2009; 69:6241 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-09-0337; PMID: 19638586
   PubMed Web of Science ®Google Scholar
• Saha MN, Jiang H, Mukai A, Chang H. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Mol Cancer Ther 2010; 9:3041 - 51; http://dx.doi.org/10.1158/1535-7163.MCT-10-0471; PMID: 21062913
   PubMed Web of Science ®Google Scholar
• Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis 2011; 2:e148; http://dx.doi.org/10.1038/cddis.2011.33; PMID: 21509038
   PubMed Web of Science ®Google Scholar
• Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285:1733 - 7; http://dx.doi.org/10.1126/science.285.5434.1733; PMID: 10481009
   PubMed Web of Science ®Google Scholar
• Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2:474 - 9; http://dx.doi.org/10.1038/nchembio809; PMID: 16862141
   PubMed Web of Science ®Google Scholar
• Di Conza G, Buttarelli M, Monti O, Pellegrino M, Mancini F, Pontecorvi A, Scotlandi K, Moretti F. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells. Mol Cancer Ther 2012; 11:1247 - 56; http://dx.doi.org/10.1158/1535-7163.MCT-11-0913; PMID: 22461661
   PubMed Web of Science ®Google Scholar
• Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256:827 - 30; http://dx.doi.org/10.1126/science.1589764; PMID: 1589764
   PubMed Web of Science ®Google Scholar
• Mazzoni E, Corallini A, Cristaudo A, Taronna A, Tassi G, Manfrini M, Comar M, Bovenzi M, Guaschino R, Vaniglia F, et al. High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma. Proc Natl Acad Sci U S A 2012; 109:18066 - 71; http://dx.doi.org/10.1073/pnas.1213238109; PMID: 23071320
   PubMed Web of Science ®Google Scholar
• Carbone M, Rizzo P, Grimley PM, Procopio A, Mew DJ, Shridhar V, de Bartolomeis A, Esposito V, Giuliano MT, Steinberg SM, et al. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 1997; 3:908 - 12; http://dx.doi.org/10.1038/nm0897-908; PMID: 9256284
   PubMed Web of Science ®Google Scholar
• Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, DeBenedetti VM, Cawley H, Welsh JA, Hansen C, Bergasa NV, et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 1996; 17:1007 - 12; http://dx.doi.org/10.1093/carcin/17.5.1007; PMID: 8640905
   PubMed Web of Science ®Google Scholar
• Aung W, Hasegawa S, Furukawa T, Saga T. Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis. Carcinogenesis 2007; 28:2047 - 52; http://dx.doi.org/10.1093/carcin/bgm090; PMID: 17434931
   PubMed Web of Science ®Google Scholar
• Villanova F, Procopio A, Rippo MR. Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies. Curr Med Chem 2008; 15:631 - 41; http://dx.doi.org/10.2174/092986708783885273; PMID: 18336278
   PubMed Web of Science ®Google Scholar
• Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 2002; 1:687 - 94; PMID: 12479365
   PubMed Web of Science ®Google Scholar
• Falleni M, Pellegrini C, Marchetti A, Roncalli M, Nosotti M, Palleschi A, Santambrogio L, Coggi G, Bosari S. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer 2005; 48:211 - 6; http://dx.doi.org/10.1016/j.lungcan.2004.10.003; PMID: 15829320
   PubMed Web of Science ®Google Scholar
• Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D, et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 2007; 29:453 - 66; PMID: 18032822
   PubMed Web of Science ®Google Scholar
• Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, Glickman JN, Yeap BY, Sugarbaker DJ, Bueno R. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 2007; 211:447 - 54; http://dx.doi.org/10.1002/path.2121; PMID: 17253596
   PubMed Web of Science ®Google Scholar
• Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277:3247 - 57; http://dx.doi.org/10.1074/jbc.M106643200; PMID: 11714700
   PubMed Web of Science ®Google Scholar
• Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21:2613 - 22; http://dx.doi.org/10.1038/sj.onc.1205353; PMID: 11965534
   PubMed Web of Science ®Google Scholar
• Kracikova M, Akiri G, George A, Sachidanandam R, Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ 2013; 20:576 - 88; http://dx.doi.org/10.1038/cdd.2012.155; PMID: 23306555
   PubMed Web of Science ®Google Scholar
• Gordon GJ, Appasani K, Parcells JP, Mukhopadhyay NK, Jaklitsch MT, Richards WG, Sugarbaker DJ, Bueno R. Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 2002; 23:1017 - 24; http://dx.doi.org/10.1093/carcin/23.6.1017; PMID: 12082024
   PubMed Web of Science ®Google Scholar
• Lazzarini R, Moretti S, Orecchia S, Betta PG, Procopio A, Catalano A. Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma. Clin Cancer Res 2008; 14:5099 - 107; http://dx.doi.org/10.1158/1078-0432.CCR-08-0255; PMID: 18698027
   PubMed Web of Science ®Google Scholar
• Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000; 83:817 - 25; http://dx.doi.org/10.1054/bjoc.2000.1327; PMID: 10952788
   PubMed Web of Science ®Google Scholar
• Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002; 16:1331 - 43; http://dx.doi.org/10.1038/sj.leu.2402535; PMID: 12094258
   PubMed Web of Science ®Google Scholar
• Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrump DS. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004; 10:1813 - 25; http://dx.doi.org/10.1158/1078-0432.CCR-0901-3; PMID: 15014036
   PubMed Web of Science ®Google Scholar
• Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, Gluch A, Kel A, Sangfelt O, Selivanova G. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009; 15:441 - 53; http://dx.doi.org/10.1016/j.ccr.2009.03.021; PMID: 19411072
   PubMed Web of Science ®Google Scholar
• Hedström E, Eriksson S, Zawacka-Pankau J, Arnér ES, Selivanova G. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle 2009; 8:3576 - 83; http://dx.doi.org/10.4161/cc.8.21.9977; PMID: 19838062
   PubMed Web of Science ®Google Scholar
• Nilsonne G, Sun X, Nyström C, Rundlöf AK, Potamitou Fernandes A, Björnstedt M, Dobra K. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med 2006; 41:874 - 85; http://dx.doi.org/10.1016/j.freeradbiomed.2006.04.031; PMID: 16934670
   PubMed Web of Science ®Google Scholar
• Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010; 42:312 - 9; http://dx.doi.org/10.1165/rcmb.2009-0060OC; PMID: 19502386
   PubMed Web of Science ®Google Scholar
• Indovina P, Giorgi F, Rizzo V, Khadang B, Schenone S, Di Marzo D, Forte IM, Tomei V, Mattioli E, D’Urso V, et al. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization. Oncogene 2012; 31:929 - 38; http://dx.doi.org/10.1038/onc.2011.286; PMID: 21785466
   PubMed Web of Science ®Google Scholar
• el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817 - 25; http://dx.doi.org/10.1016/0092-8674(93)90500-P; PMID: 8242752
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27 - 55; http://dx.doi.org/10.1016/0065-2571(84)90007-4; PMID: 6382953
   PubMedGoogle Scholar
• Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986; 31:229 - 34; http://dx.doi.org/10.1002/jso.2930310402; PMID: 3724177
   PubMed Web of Science ®Google Scholar
• Indovina P, Marcelli E, Di Marzo D, Casini N, Forte IM, Giorgi F, Alfano L, Pentimalli F, Giordano A. Abrogating G 2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Cancer Biol Ther 2013; 15; PMID: 24365782
   PubMed Web of Science ®Google Scholar